European Journal of Cancer
Volume 45, Issue 17 , Pages 2992-2999 , November 2009

Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy

  • Ralf Gertler

      Affiliations

    • Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    • Corresponding Author InformationCorresponding author: Address: Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, 81675 Munich, Germany. Tel.: +49 89 4140 5135; fax: +49 89 4140 7207.
    • ,
  • Robert Rosenberg

      Affiliations

    • Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    • ,
  • Tibor Schuster

      Affiliations

    • Institute of Medical Statistics and Epidemiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    • ,
  • Helmut Friess

      Affiliations

    • Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Received 18 June 2009 ,Accepted 17 July 2009.

References 

  1. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93:583–596
  2. Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed.. New York: Wiley-Liss; 1997;
  3. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed.. New York: Springer-Verlag; 2002;
  4. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444–50.
  5. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–3419
  6. Figueredo A, Germond C, Maroun J, et al. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control. 1997;1:379–392
  7. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–3407
  8. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and how much?. J Clin Oncol. 2004;22:1797–1806
  9. International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 Colon Cancer. J Clin Oncol 1999;17:1356–63.
  10. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999–4005
  11. Schmiegel W, Pox C, Reinacher-Schick A, et al. S3-guideline “Colorectal Cancer” 2004/2008. Z Gastroenterol. 2008;46:1–73
  12. Saville DJ. Multiple comparison procedures: the practical solution. The American Statistician. 1990;44:174–180
  13. Nauta R, Stablein DM, Holyoke ED. Survival of patients with stage B2 colon carcinoma: the Gastrointestinal Tumour Study Group experience. Arch Surg. 1989;124:180–182
  14. O’Connell JB, Maggard MA KOCY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–1425
  15. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med. 1990;322:352–358
  16. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med. 2004;350:2343–2351
  17. Taal BG, Van Tinteren H, Zoetmulder FA, et al. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Brit J Cancer. 2001;85:1437–1443
  18. Sargent DJ, Golberg RM, Jacobsen SD, et al. A pooled analysis of adjuvant chemotherapy for resected colo cancer in elderly patients. New Engl J Med. 2001;345:1091–1097
  19. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol. 1990;8:1466–1475
  20. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17:1349–1355
  21. Liver Infusion Meta-analysis Group: portal vein chemotherapy for colorectal cancer:a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst. 1997;89:497–505
  22. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020–9.
  23. Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed.. New York: Wiley-Liss; 1997;
  24. Sobin LH, Greene FL. TNM classification: clarification of number of regional lymph nodes for pN0. Cancer. 2001;92:452
  25. Buyse M, Piedbois P. Should Dukes’ B patients receive adjuvant therapy? A statistical perspective. Semin Oncol. 2001;28:20–24
  26. Sobrero A, Köhne CH. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer?. Lancet Oncol. 2006;7:515–517
  27. Swanson RS, Compton CC, Stewart AK, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10:65–71
  28. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21:2912–2919
  29. Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51:503–507
  30. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal ancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–994
  31. Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174:27–32
  32. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and hTERT expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22:1807–1814
  33. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based chemotherapy for colon cancer. New Engl J Med. 2003;349:247–257
  34. Wolmark N, Fisher B, Wieand HS, et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg. 1984;199:375–382
  35. Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg. 1983;198:743–752
  36. Steinberg SM, Barkin JS, Kaplan RS, et al. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer. 1986;57:1866–1870
  37. Witzig TE, Loprinzi CL, Gancheroff NJ, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer. 1991;68:879–888

PII: S0959-8049(09)00545-0

doi: 10.1016/j.ejca.2009.07.008

European Journal of Cancer
Volume 45, Issue 17 , Pages 2992-2999 , November 2009

Article Tools

* Image Usage & Resolution